PMID- 1966815
OWN - NLM
STAT- MEDLINE
DCOM- 19920312
LR  - 20141120
IS  - 0921-8319 (Print)
IS  - 0921-8319 (Linking)
VI  - 2 Suppl
DP  - 1990
TI  - Enhancement of the expression of eosinophil IgE receptor (Fc epsilon R2) and its 
      function by platelet-activating factor.
PG  - S177-86
AB  - Eosinophils possess low-affinity Fc immunoglobulin E (IgE) receptors (Fc epsilon 
      R2). We have compared platelet-activating factor (PAF) with lyso-PAF, leukotriene 
      B4 (LTB4) and histamine for their ability to influence the binding of a native 
      myeloma IgE to normal-density human eosinophils, using flow cytometry and a 
      fluorescein-conjugated anti-IgE polyclonal antibody. Preincubation with PAF gave 
      a dose- and time-dependent increase in IgE binding optimal at 10(-7) M (P less 
      than 0.01) and 30 min respectively. A smaller but significant effect was observed 
      with LTB4 and histamine (optimal at 10(-7) M (P less than 0.01) and 10(-5) M (P 
      less than 0.05) respectively). Diluent alone or lyso-PAF had no effect. These 
      results suggest enhanced expression of Fc epsilon R2 by stimulated eosinophils. 
      Further confirmation of enhancement was obtained using two functional assays, 
      i.e., cytotoxicity and mediator (LTC4) generation. IgE-dependent cytotoxicity 
      against schistosomula of Schistosoma mansoni was enhanced by prior incubation of 
      normal eosinophils with PAF (optimal at 10(-7) M), but not lyso-PAF. No LTC4 was 
      detectable following incubation of unstimulated eosinophils with S. mansoni 
      coated with specific IgE. Preincubation of these cells with PAF (10(-7) M) 
      resulted in the generation of 4.4 pmol of LTC4 per 10(6) cells. Our data 
      demonstrate that normal-density eosinophil Fc epsilon R2 expression can be 
      up-regulated in vitro by PAF and LTB4 and that these changes are accompanied by 
      enhanced functional properties.
FAU - Walsh, G M
AU  - Walsh GM
AD  - Department of Allergy and Clinical Immunology, National Heart and Lung Institute, 
      London, U.K.
FAU - Moqbel, R
AU  - Moqbel R
FAU - Nagakura, T
AU  - Nagakura T
FAU - Iikura, Y
AU  - Iikura Y
FAU - Kay, A B
AU  - Kay AB
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Lipid Mediat
JT  - Journal of lipid mediators
JID - 8913460
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (O-deacetyl platelet activating factor)
RN  - 0 (Platelet Activating Factor)
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, IgE)
RN  - 0 (SRS-A)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 820484N8I3 (Histamine)
SB  - IM
MH  - Animals
MH  - Antigens, Differentiation, B-Lymphocyte/*drug effects/physiology
MH  - Cytotoxicity, Immunologic/drug effects
MH  - Eosinophils/*drug effects/immunology
MH  - Histamine/pharmacology
MH  - Humans
MH  - Immunoglobulin E/metabolism
MH  - In Vitro Techniques
MH  - Leukotriene B4/pharmacology
MH  - Platelet Activating Factor/analogs & derivatives/*pharmacology
MH  - Receptors, Fc/*drug effects/physiology
MH  - Receptors, IgE
MH  - SRS-A/biosynthesis
MH  - Schistosoma mansoni/immunology
EDAT- 1990/01/01 00:00
MHDA- 1990/01/01 00:01
CRDT- 1990/01/01 00:00
PHST- 1990/01/01 00:00 [pubmed]
PHST- 1990/01/01 00:01 [medline]
PHST- 1990/01/01 00:00 [entrez]
PST - ppublish
SO  - J Lipid Mediat. 1990;2 Suppl:S177-86.